• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluating physician confidence and barriers in prescribing tolvaptan for ADPKD management: a comprehensive online survey study.

作者信息

Ebrahimi Niloufar, Vakhshoori Mehrbod, Chebib Fouad, Garimella Pranav S, Caliskan Yasar, Abdipour Amir, Norouzi Sayna

机构信息

Department of Medicine, Division of Nephrology, Loma Linda University Medical Center, Loma Linda, CA, USA.

Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA.

出版信息

J Nephrol. 2024 Nov;37(8):2429-2431. doi: 10.1007/s40620-024-02053-z. Epub 2024 Aug 17.

DOI:10.1007/s40620-024-02053-z
PMID:39152364
Abstract
摘要

相似文献

1
Evaluating physician confidence and barriers in prescribing tolvaptan for ADPKD management: a comprehensive online survey study.评估医生在为常染色体显性多囊肾病管理开具托伐普坦处方时的信心和障碍：一项全面的在线调查研究。
J Nephrol. 2024 Nov;37(8):2429-2431. doi: 10.1007/s40620-024-02053-z. Epub 2024 Aug 17.
2
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.托伐普坦治疗快速进展型常染色体显性多囊肾病的实用指南。
J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.
3
TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.托伐普坦在重症新生儿常染色体显性多囊肾病（ADPKD）中的应用：药学挑战
Arch Dis Child. 2016 Sep;101(9):e2. doi: 10.1136/archdischild-2016-311535.61.
4
A Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.托伐普坦治疗常染色体显性遗传多囊肾病关键性试验中他汀类药物的使用分析。
Clin J Am Soc Nephrol. 2020 May 7;15(5):643-650. doi: 10.2215/CJN.08170719. Epub 2020 Apr 2.
5
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.TEMPO（托伐普坦治疗常染色体显性遗传多囊肾病及其结局的疗效和安全性）3-4 研究的原理和设计。
Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.
6
Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?托伐普坦用于儿童常染色体显性多囊肾病：何去何从？
Kidney Dis (Basel). 2021 Sep;7(5):343-349. doi: 10.1159/000517186. Epub 2021 Jul 2.
7
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.托伐普坦治疗对常染色体显性多囊肾病肾功能下降的长期益处建模：使用常染色体显性多囊肾病结局模型的探索性分析
BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5.
8
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.托伐普坦在不同慢性肾脏病阶段对常染色体显性遗传性多囊肾病的疗效：TEMPO 3:4试验结果
Clin J Am Soc Nephrol. 2016 May 6;11(5):803-811. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.
9
Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment.在接受托伐普坦治疗的 ADPKD 患者中，SGLT2 抑制剂达格列净具有额外的肾脏保护作用。
CEN Case Rep. 2024 Oct;13(5):419-424. doi: 10.1007/s13730-024-00859-1. Epub 2024 Mar 18.
10
10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study.常染色体显性多囊肾病中托伐普坦信息的依从性和满意度的10年评估：一项单中心试点研究
Patient Prefer Adherence. 2021 Sep 4;15:1941-1952. doi: 10.2147/PPA.S325738. eCollection 2021.

引用本文的文献

1
Comparative validation of the Mayo Clinic imaging classification and PROPKD score for predicting ADPKD progression across diverse ethnic cohorts.梅奥诊所影像学分类和PROPKD评分在不同种族队列中预测常染色体显性多囊肾病进展的比较验证
J Nephrol. 2025 Apr 9. doi: 10.1007/s40620-025-02282-w.
2
Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.托伐普坦的安全性评估：使用美国食品药品监督管理局不良事件报告系统数据库进行的真实世界不良事件分析
Front Pharmacol. 2025 Jan 9;15:1509310. doi: 10.3389/fphar.2024.1509310. eCollection 2024.
3
Low-dose tolvaptan to control disease progression in Chinese patients with autosomal dominant polycystic kidney disease: a retrospective cohort study.

本文引用的文献

1
An update on treatments for autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病治疗进展。
JAAPA. 2023 Jun 1;36(6):11-16. doi: 10.1097/01.JAA.0000931420.46207.82.
2
Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease.使用托伐普坦治疗常染色体显性多囊肾病的最新进展。
Korean J Intern Med. 2023 May;38(3):322-331. doi: 10.3904/kjim.2022.376. Epub 2023 Apr 25.
3
Drug management of autosomal dominant polycystic kidney disease.常染色体显性多囊肾病的药物治疗
低剂量托伐普坦控制中国常染色体显性多囊肾病患者疾病进展：一项回顾性队列研究
Transl Androl Urol. 2024 Oct 31;13(10):2307-2321. doi: 10.21037/tau-24-448. Epub 2024 Oct 28.
Aust Prescr. 2022 Oct;45(5):167-170. doi: 10.18773/austprescr.2022.052. Epub 2022 Oct 4.
4
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.托伐普坦治疗常染色体显性遗传性多囊肾病的应用进展：代表欧洲肾脏协会遗传性肾脏疾病工作组、欧洲罕见肾脏疾病参考网络和多囊肾病国际组织的共识声明。
Nephrol Dial Transplant. 2022 Apr 25;37(5):825-839. doi: 10.1093/ndt/gfab312.
5
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.托伐普坦治疗快速进展型常染色体显性多囊肾病的实用指南。
J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.
6
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗晚期常染色体显性遗传性多囊肾病。
N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.
7
Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease.常染色体显性遗传性肾病的进展：慢性肾病分期转变的测量
Drugs Context. 2015 Apr 17;4:212275. doi: 10.7573/dic.212275. eCollection 2015.
8
Tolvaptan in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传多囊肾病。
N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.